Clinical trial NCT01342770: Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer
Official title: Pioglitazone as a Candidate Chemoprevention Agent for Lung Cancer: A Pilot Trial Using a Pre-surgical Model in Early Stage NSCLC
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Stage IA Non-Small Cell Lung Carcinoma
Stage IB Non-Small Cell Lung Carcinoma
Stage IIA Non-Small Cell Lung Carcinoma
Stage IIB Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2011-04-27
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This pilot phase II trial studies how well pioglitazone works in treating patients with stage IA-IIIA non-small cell lung cancer. Pioglitazone hydrochloride may slow the growth of tumor cells and may be an effective treatment for non-small cell lung cancer.

Detailed description: PRIMARY OBJECTIVES:

I. To evaluate the mechanism(s) of action of pioglitazone as a candidate chemopreventive agent for lung cancer by investigating the effects on Ki-67 defined in non-small cell lung cancer (NSCLC) tumor tissue.

SECONDARY OBJECTIVES:

I. To determine the effects of pioglitazone on multiple markers listed below:

* Tumor tissue: caspase-3, cyclin D1, p21/Waf1, peroxisome proliferative activated receptor, gamma (PPARγ), mucin 1 (MUC1).
* Premalignant tissue: Ki-67, caspase-3, PPARγ.
* Histologically normal tissue: Ki-67, PPARγ. II. To evaluate the toxicity and safety of pioglitazone in this patient population.

III. To analyze the expression of serum markers that are affected by pioglitazone.

IV. To describe the effects of limited treatment with pioglitazone on tumor metabolic activity as determined by FDG-PET (assessed before and after a minimum of 2 weeks of treatment).

OUTLINE:

Patients receive pioglitazone hydrochloride orally (PO) once daily (QD) for 14-42 days. Patients then undergo surgery.

Eligibility criteria: Inclusion Criteria:

* Suspected or biopsy-proven NSCLC
* Willingness to provide biopsy tissue for correlative studies
* Candidate for pulmonary resection; must be able to schedule \>= 14 days and =\< 42 days between registration and surgery to allow for treatment with pioglitazone
* Ability to understand and the willingness to sign a written informed consent document
* Ability and willingness to swallow oral tablets
* Ability and willingness to undergo two bronchoscopies (before treatment and at the time of surgery)

  * For those participants who are undergoing mediastinoscopy as part of their standard-of-care, the pre-treatment bronchoscopy may be performed during the mediastinoscopy; if the participant remains eligible for definitive surgical resection after the mediastinoscopy, the participant may proceed to registration and pioglitazone treatment
* Current or former smoker with a \>= 10 pack-year smoking history
* Women of child-bearing potential and men who agree to use adequate contraception for the duration of study participation; women must not be pregnant or lactating; women of child-bearing potential (women considered not of childbearing potential if they are at least two years postmenopausal and/or surgically sterile) must have used adequate contraception (abstinence; barrier methods such as intrauterine device \[IUD\], diaphragm with spermicidal gel, condom, or others; and hormonal methods such as birth control pills or others) since her last menses prior to study entry; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

Exclusion Criteria:

* Receiving any other investigational agents
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to pioglitazone
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant or lactating woman
* Currently treated diabetes
* Participants with \>= class II New York Heart Association (NYHA) congestive heart failure or history of congestive heart failure
* Participants with \>= grade 2 (moderate) edema
* Participants currently receiving an inhibitor of cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8) (gemfibrozil, ketoconazole, quercetin, trimethoprim), or an inducer of CYP2C8 (cortisol, dexamethasone, phenobarbital, rifampin), or cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) substrate
* Prior neoadjuvant therapy for NSCLC
* History of bladder cancer or in situ bladder cancer

Primary outcomes:
measure: Percent Change in Ki-67 by Immunohistochemistry (IHC)
timeFrame: Baseline and at the time of surgery, after 42 days of treatment
Secondary outcomes:
measure: Change in Apoptosis Assessment (e.g., Caspase-3)
timeFrame: Baseline and at the time of surgery, after 42 days of treatment
measure: Change in Levels of Serum CA-153
timeFrame: Baseline and at the time of surgery, after 42 days of treatment
measure: Change in Levels of Serum CRP
timeFrame: Baseline and at the time of surgery, after 42 days of treatment
measure: Gene Expression Analysis of RNA From Bronchial Brush Cells
timeFrame: Up to the time of surgery, after 42 days of treatment
measure: Incidence of Adverse Events Graded According to Common Terminology Criteria for Adverse Events Version 4.0
timeFrame: Up to the time of surgery, after 42 days of treatment
measure: Number of Participants With Clinical Response, Based on Response Evaluation Criteria in Solid Tumors ( RECIST) Version 1.1
timeFrame: Up to the time of surgery, after 42 days of treatment
measure: Number of Participants With Complete Pathologic Response
timeFrame: Up to the time of surgery, after 42 days of treatment
measure: Percent Change in Cyclin D1
timeFrame: Baseline to the time of surgery, after 42 days of treatment
measure: Percent Change in MUC1
timeFrame: Baseline to the time of surgery, after 42 days of treatment
measure: Percent Change in p21
timeFrame: Baseline to the time of surgery, after 42 days of treatment
measure: Percent Change in PPARy
timeFrame: Baseline to the time of surgery, after 42 days of treatment
measure: Percent Change in SUVmax From the PET Scan
timeFrame: Baseline to the time of surgery, after 42 days of treatment
measure: Pre-intervention SUV of PET Scan
timeFrame: Baseline
measure: Post-intervention SUV of PET Scan
timeFrame: Time of surgery, after 42 days of treatment
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Paul Limburg
role: PRINCIPAL_INVESTIGATOR
References: